Nanomics Biotechnology

Nanomics Biotechnology is an innovative Israeli life sciences company focused on the development of high-resolution liquid biopsy platforms for early cancer detection. The company utilizes proprietary technology to isolate and analyze extracellular vesicles (EVs), which serve as rich sources of biomarkers reflecting the physiological state of their cells of origin. By combining advanced molecular profiling with machine learning algorithms, Nanomics identifies specific signatures within the EV cargo to detect malignancies at their earliest, most treatable stages. Their current pipeline includes diagnostic programs for lung, pancreatic, and ovarian cancers, addressing significant unmet needs in oncology screening. The company's non-invasive approach aims to replace or supplement traditional tissue biopsies with a simple blood test.